Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM ...

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has approved ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis transmembrane ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced ...

The new pill is seen as a ‘major leap forward’ for hundreds of patients living with the rarest forms of cystic fibrosis ...

Alyftrek (vanza triple), Vertex’s new once-a-day oral triple combination medicine for treating people with CF aged six years and older, has the potential to provide better patient benefit than ...

ALYFTREK is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B) and should only be considered when there is a clear medical need, and benefit outweighs risk.